Administration of 4-Factor Prothrombin Complex Concentrate as an Antidote for Intracranial Bleeding in Patients Taking Direct Factor Xa Inhibitors
- 1 December 2015
- journal article
- Published by Elsevier BV in World Neurosurgery
- Vol. 84 (6), 1956-1961
- https://doi.org/10.1016/j.wneu.2015.08.042
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Reversal of Apixaban Induced Alterations in Hemostasis by Different Coagulation Factor Concentrates: Significance of Studies In Vitro with Circulating Human BloodPLOS ONE, 2013
- Oral Apixaban for the Treatment of Acute Venous ThromboembolismThe New England Journal of Medicine, 2013
- Clinical review: Clinical management of new oral anticoagulants: a structured review with emphasis on the reversal of bleeding complicationsCritical Care, 2013
- Apixaban for Extended Treatment of Venous ThromboembolismThe New England Journal of Medicine, 2013
- Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary EmbolismThe New England Journal of Medicine, 2012
- Apixaban versus Warfarin in Patients with Atrial FibrillationThe New England Journal of Medicine, 2011
- Apixaban versus Enoxaparin for Thromboprophylaxis after Hip ReplacementThe New England Journal of Medicine, 2010
- Apixaban or Enoxaparin for Thromboprophylaxis after Knee ReplacementThe New England Journal of Medicine, 2009
- Evaluation and comparison of coagulation factor activity in fresh-frozen plasma and 24-hour plasma at thaw and after 120 hours of 1 to 6°C storageTransfusion, 2009
- Biochemical comparison of seven commercially available prothrombin complex concentratesInternational Journal of Clinical Practice, 2008